Sonidegib (INN), sold under the brand name Odomzo, is a medication used to treat cancer.^[1]

Sonidegib is Hedgehog signaling pathway inhibitor (via smoothened antagonism).^[5][6]

It was approved for medical use in the United States and in the European Union in 2015^[7][1][8][9]

It is indicated for the treatment of adults with locally advanced basal-cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.^[1]

Sonidegib is administered by mouth. Common side effects include muscle spasms, hair loss, fatigue, abdominal pain, nausea, headache, and weight loss.^[1]

Sonidegib binds to and inhibits smoothened to inhibit activation of the Hedgehog pathway. Sonidegib is primarily metabolized by CYP3A and is eliminated hepatically.^[1]

It has been investigated as a potential treatment for:

• Pancreatic cancer^{[10][11][12][13]}
• Breast cancer^[14][15]
• Basal cell carcinoma of the skin^[16][17][18]
• Small cell lung cancer^[19]
• Medulloblastoma^[20][21]
• Advanced solid tumors (including ovarian, breast, pancreatic, stomach, oesophageal cancers and glioblastoma multiforme)^[22][23][24]
• Acute leukemia^[25] and chronic myeloid leukemia^[26]
• Myelofibrosis and essential thrombocythaemia^[27]

It has demonstrated significant efficacy against melanoma in vitro and in vivo.^[28] It also demonstrated efficacy in a mouse model of pancreatic cancer.^[29]